Updated findings from SunRISe-1 also showed that all but 1 responder achieved complete response within 12 weeks of treatment with the targeted gemcitabine delivery system.
A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone."